| dc.contributor.author |
Kodisinghe, S.K. |
|
| dc.contributor.author |
Niriella, M.A. |
|
| dc.date.accessioned |
2016-03-03T09:59:44Z |
|
| dc.date.available |
2016-03-03T09:59:44Z |
|
| dc.date.issued |
2015 |
|
| dc.identifier.citation |
Sri Lanka Journal of Diabetes Endocrinology and Metabolism.2015;5(1):28-33 |
en_US |
| dc.identifier.issn |
2012-998X |
|
| dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/12035 |
|
| dc.description.abstract |
Non-alcoholic fatty liver disease (NAFLD)it is the commonest cause of chronic liver disease in developed countries and is rapidly increasing in the Asia-Pacific region. NAFLD has important long term health implications. There is increased overall mortality most commonly from cardiovascular disease, and also increased liver-related mortality. Treatment options available for NAFLD include general measures at managing obesity and correcting the metabolic syndrome and liver-directed therapies aimed at reducing the liver inflammation and hepatocellular injury. This article reviews the current evidence based management of NAFLD and associated metabolic comorbidities. |
en_US |
| dc.language.iso |
en_US |
en_US |
| dc.publisher |
Endocrine Society of Sri Lanka |
en_US |
| dc.subject |
non-alcoholic fatty liver disease |
en_US |
| dc.title |
Evidence-based management of non-alcoholic fatty liver disease |
en_US |
| dc.type |
Article |
en_US |